Cancer Immunology Reserch

Genomic and immune landscape of recurrent and/or metastatic squamous cell carcinoma of the head and neck progressing on anti-PD1 treatment

by

Cancer Immunol Res. 2026 Feb 10. doi: 10.1158/2326-6066.CIR-25-0979. Online ahead of print. ABSTRACT Anti-PD1 therapies improve survival in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN), but only a minority of patients achieve durable responses. The mechanisms driving resistance to anti-PD1 in SCCHN remain poorly understood. Using the IMMUcan multi-omics workflow, we … Read more

Neoadjuvant endocrine treatment plus mammaglobin-A DNA vaccine induces antitumor immune responses in the primary tumor and peripheral blood of breast cancer patients: Insights from a phase 1b clinical trial

by

Cancer Immunol Res. 2026 Feb 6. doi: 10.1158/2326-6066.CIR-25-0666. Online ahead of print. ABSTRACT Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in >50% of breast cancer (BC) patients. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients … Read more

Concurrent Pituitary and Thyroid Immune-Related Adverse Events after Immune Checkpoint Inhibitors Associated with HLA-DR15-related Haplotypes

by

Cancer Immunol Res. 2026 Feb 4. doi: 10.1158/2326-6066.CIR-25-0693. Online ahead of print. ABSTRACT Some patients undergoing immune checkpoint blockade treatment develop immune-related adverse events (irAEs) affecting multiple organs, but whether pituitary and thyroid dysfunction are prone to co-occur is unclear. A total of 1,014 patients treated at Nagoya University Hospital were prospectively assessed for pituitary … Read more

CCL1-AMFR facilitates glioblastoma progression by modulating the crosstalk between glioma cells and tumor-associated macrophages

by

Cancer Immunol Res. 2026 Jan 30. doi: 10.1158/2326-6066.CIR-25-0646. Online ahead of print. ABSTRACT The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAMs), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1-AMFR axis as a critical contributor to GBM progression … Read more

Computational modeling of cellular influence delineates functionally relevant and distinct cellular neighborhoods in primary and metastatic pancreatic ductal adenocarcinoma

by

Cancer Immunol Res. 2026 Jan 23. doi: 10.1158/2326-6066.CIR-25-0844. Online ahead of print. ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with liver metastases significantly worsening outcomes. However, features of the tumor microenvironment (TME) that are distinct between primary and metastatic sites remain poorly defined. Cellular neighborhoods within the TME are recognized as functional … Read more

Removal of Interstitial Hyaluronan Facilitates Subcutaneous Administration and Lymphatic Delivery of Anti-CTLA4 and Improves Antitumor Efficacy

by

Cancer Immunol Res. 2026 Jan 27:OF1-OF13. doi: 10.1158/2326-6066.CIR-25-0256. Online ahead of print. ABSTRACT Subcutaneous administration is an increasingly patient-preferred, alternative route of administration for monoclonal antibodies (mAb). To overcome the dose-volume restriction with subcutaneous administration and enable the large mAb doses typically required for immunotherapy, recombinant human hyaluronidase PH20 is co-dosed to transiently depolymerize hyaluronan … Read more

Regulatory T-cell sensing of extracellular ATP via P2RX7 promotes their accumulation and suppression and drives lung tumor growth

by

Cancer Immunol Res. 2026 Jan 21. doi: 10.1158/2326-6066.CIR-25-0567. Online ahead of print. ABSTRACT Lung cancer is the leading cause of cancer-related deaths worldwide and, despite advances in treatment, immune suppression remains an obstacle to effective therapy. Effector CD4+ T cells (CD4+ Teffs) are critical for antitumor immunity, but their function is often inhibited by regulatory … Read more

Ex Vivo Immuno-Oncology Platform Reveals Spatial T Cell Infiltration Patterns Linked to ATR Inhibition Responses in High-Grade Serous Ovarian Cancer

by

Cancer Immunol Res. 2026 Jan 21. doi: 10.1158/2326-6066.CIR-25-0743. Online ahead of print. ABSTRACT Identifying new therapeutic approaches in high-grade serous ovarian cancer (HGSC) requires the development of more accurate preclinical models that replicate the patient-specific tumor and its microenvironment. To address this, we established immunocompetent patient-derived cultures (iPDCs) for HGSC, cultured on a physiologically relevant … Read more

Anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy bb21217 for relapsed and refractory multiple myeloma: results from the phase 1 CRB-402 study

by

Cancer Immunol Res. 2026 Jan 21. doi: 10.1158/2326-6066.CIR-24-0527. Online ahead of print. ABSTRACT Chimeric antigen receptor (CAR) T-cell therapy enriched for a memory-like phenotype may persist and function longer than a non-enriched product, thereby improving duration of response (DOR). We conducted a phase 1 study with bb21217 (NCT03274219), an anti-B-cell maturation antigen CAR T-cell therapy … Read more

deneme bonusu veren siteler - canlı bahis siteleri - casino siteleri casino siteleri deneme bonusu veren siteler canlı casino siteleri error code: 520